1.Influence factors and predictors in anti-viral therapy for chronic hepatitis C.
Sheng JIN ; Wei-ping ZHOU ; Da-zhi ZHANG
Chinese Journal of Hepatology 2004;12(2):124-125
Alanine Transaminase
;
blood
;
Genotype
;
Hepacivirus
;
classification
;
genetics
;
Hepatitis C, Chronic
;
drug therapy
;
immunology
;
virology
;
Humans
;
RNA, Viral
;
blood
2.HCV RNA in PBMC as predictor of the response to antiviral therapy in chronic hepatitis C.
Dao-zhen XU ; Zheng-qin LI ; Yao XIE
Chinese Journal of Hepatology 2004;12(2):76-78
OBJECTIVETo investigate the predictive value of HCV RNA in PBMC of patients with chronic hepatitis C to IFN treatment.
METHODSThe HCV RNAs in PBMC were detected at the end of treatment, and 24 week and 1 year follow up after end treatment, in 16 patients who acquired complete response to IFN in 12 weeks of 24 weeks therapy.
RESULTS9 patients were HCV RNA positive in their PBMC at the end of treatment, the serum HCV RNA of 8 turned positive after 24 weeks and 1 year follow-up. In 7 patients with negative HCV RNA in PBMC, only two patients relapsed in serum HCV RNA after 1 year follow-up, and others remained viral response after 3.5 years.
CONCLUSIONHCV RNA in PBMC at the end of treatment was a predictor of the durable response to antiviral therapy in chronic hepatitis C.
Adult ; Female ; Hepatitis C, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; therapeutic use ; Leukocytes, Mononuclear ; virology ; Male ; Middle Aged ; RNA, Viral ; blood ; Recombinant Proteins
3.Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence is not a edictive factor for response to interferon-alpha therapy and development of patocellular carcinoma.
Si Hyun BAE ; Young Min PARK ; Duck Gi YOO ; Jong Young CHOI ; Byung Hun BYUN ; Jin Mo YANG ; Chang Don LEE ; Sang Bok CHA ; Doo Ho PARK ; Boo Sung KIM
Journal of Korean Medical Science 2000;15(1):53-58
Genetic changes between codons 2209 and 2248 of NS5A of genotype 1b hepatitis C virus (HCV-1b) have been reported to be associated with the sensitivity to interferon-alpha (IFN-alpha). The present study was performed to analyze such relationship in Korean patients with chronic hepatitis C and HCV-1b (n=19), including 12 chronic hepatitis C patients treated with IFN-alpha, 3 chronic hepatitis C patients without treatment as controls, and 4 patients with hepatocellular carcinoma (HCC). Two serum samples, before and after the treatment, were analyzed for the mutations by reverse transcription-polymerase chain reaction, cloning and sequencing. The mutations were identified in 32% (6/19), including five intermediate type (1-3 mutations) and one mutant type (4 or more). In 12 patients treated with IFN-alpha, the number of amino acid substitutions in NS5A2209-2248 was not associated with outcome of the treatment.
Adult
;
Aged
;
Amino Acid Sequence
;
Antiviral Agents/therapeutic use*
;
Base Sequence
;
Carcinoma, Hepatocellular/virology*
;
Carcinoma, Hepatocellular/blood
;
Codon
;
Female
;
Genotype
;
Hepatitis C, Chronic/virology*
;
Hepatitis C, Chronic/drug therapy*
;
Hepatitis C, Chronic/blood
;
Hepatitis C-Like Viruses/isolation & purification
;
Hepatitis C-Like Viruses/genetics*
;
Hepatitis C-Like Viruses/classification
;
Human
;
Interferon-alpha/therapeutic use*
;
Liver Neoplasms/virology*
;
Liver Neoplasms/blood
;
Male
;
Middle Age
;
Molecular Sequence Data
;
Mutation*
;
Prognosis
;
Reverse Transcriptase Polymerase Chain Reaction
4.Life quality analysis of hepatitis C patients with liver cirrhosis undergoing antiviral therapy following splenectomy.
Guangxi JI ; Yonghong GUO ; Lin CHEN ; Ying ZHANG ; Yu HE ; Li MA ; Yu WANG ; Zhiyuan MA ; Cheng CHENG ; Zhansheng JIA
Chinese Journal of Hepatology 2014;22(3):195-199
OBJECTIVETo evaluate the effect of antiviral therapy on the quality of life (QOL) of patients with chronic hepatitis C (CHC) and cirrhosis during the 5-year period following splenectomy to treat hypersplenism.
METHODSData of patients with CHC and cirrhosis who had undergone treatment for hypersplenism were retrospectively selected from the hospital database of medical records. The patients were first grouped according to the hypersplenism treatment: splenectomy (group A, 28 cases) and conservative/non-operative (group B, 30 cases). Sub-grouping was carried out according to the CHC treatment: interferon-alpha-2a and ribavirin (15 cases in the A1 group, and 19 cases in the B1 group) and non-antiviral (13 cases in the A2 group, and 11 cases in the B2 group). To determine the intergroup differences in QOL during the 5-year period following the hypersplenism treatment, the QOL was assessed by chronic liver disease questionnaire (CLDQ), listing of specific symptoms (SS), and the World Health Organization QOL scale (WHOQOL-BREF).
RESULTSBetween-group statistical comparison of the subjective feeling, physiological status, mental state, and social life relationship of the patients showed no significant differences among the patients who received splenectomy compared to those who received the conservative treatment. However, the QOL of splenectomy-treated patients who received non-antiviral CHC treatment was worse than that of the patients who were given conservative treatment for the hypersplenism and antiviral therapy for the CHC. The patients who received splenectomy and antiviral therapy had better QOL than the other patient group(3.69 +/- 0.75 vs 2.15 +/- 0.98, P = 0.0003).
CONCLUSIONSplenectomy followed by antiviral therapy may improve the QOL of patients with CHC-related cirrhosis and hypersplenism.
Adult ; Antiviral Agents ; therapeutic use ; Female ; Hepatitis C, Chronic ; complications ; drug therapy ; Humans ; Liver Cirrhosis ; drug therapy ; virology ; Male ; Middle Aged ; Quality of Life ; Retrospective Studies ; Splenectomy ; Treatment Outcome
5.Antiviral treatment for cirrhosis due to hepatitis C: a review.
Aravindh SOMASUNDARAM ; Jayanthi VENKATARAMAN
Singapore medical journal 2012;53(4):231-235
Chronic hepatitis C infection is an important cause of cirrhosis and hepatocellular carcinoma (HCC). Antiviral therapy (AVT) for patients with cirrhosis due to hepatitis C may retard the progression of cirrhosis and prevent both the development of HCC as well as the recurrence of hepatitis C following liver transplantation. This review highlights the issues associated with AVT for patients with compensated and decompensated cirrhosis due to hepatitis C virus.
Antiviral Agents
;
therapeutic use
;
Carcinoma, Hepatocellular
;
prevention & control
;
virology
;
Disease Progression
;
Hepacivirus
;
Hepatitis C, Chronic
;
complications
;
drug therapy
;
Humans
;
Liver Cirrhosis
;
drug therapy
;
virology
;
Liver Neoplasms
;
prevention & control
;
virology
;
Liver Transplantation
;
Secondary Prevention
6.Acute Exacerbation of Hepatitis in Liver Cirrhosis with Very High Levels of alpha-Fetoprotein But No Occurrence of Hepatocellular Carcinoma.
Jin Soo BAE ; Sang Jong PARK ; Kwang Bo PARK ; So Ya PAIK ; Jin Kyung RYU ; Chang Kyu CHOI ; Tae Joon HWANG
The Korean Journal of Internal Medicine 2005;20(1):80-85
Aminotransferase levels do not always increase during acute hepatitis or during an acute flare-up of chronic hepatitis. Persistently increased levels of serum alpha-Fetoprotein in an adult with liver disease suggest not only the presence or progression of hepatocellular carcinoma or its recurrence after hepatic resection or after other therapeutic approaches such as chemotherapy or chemoembolization, but also it suggests that there is an acute exacerbation of hepatitis or liver cirrhosis. We report here on two unusual cases of HBV- and HCV-related liver cirrhosis with acute exacerbation of hepatitis in which there was an insignificant elevation of the aminotransferase levels, but there were markedly increased alpha-Fetoprotein levels observed. The levels of alpha-Fetoprotein decreased gradually in both cases since the beginning of antiviral therapy, which implies that the increased levels were due to aggravation of the accompanying hepatitis. These cases also emphasize that using only the measurement of alpha-Fetoprotein is not sufficient for the diagnosis of hepatocellular carcinoma, and that this diagnosis also requires a more specific measurement such as AFP L3 along with the standard imaging studies.
Antiviral Agents/therapeutic use
;
Female
;
Hepatitis B, Chronic/*complications/drug therapy
;
Hepatitis C, Chronic/*complications/drug therapy
;
Humans
;
Liver Cirrhosis/virology
;
Male
;
Middle Aged
;
Transaminases/blood
;
alpha-Fetoproteins/*analysis
7.Occult Hepatitis B Virus Infection in Chronic Hepatitis C.
The Korean Journal of Gastroenterology 2013;62(3):154-159
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.
Carcinoma, Hepatocellular/complications
;
DNA, Viral/analysis
;
Hepacivirus/genetics
;
Hepatitis B/*complications/*diagnosis/drug therapy
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/*complications/*diagnosis/drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Liver/virology
;
Liver Neoplasms/complications
9.Current status of liver disease in Korea: Hepatitis C.
The Korean Journal of Hepatology 2009;15(Suppl 6):S25-S28
Chronic hepatitis C (CHC) is the third most common cause of chronic liver disease and hepatocellular carcinoma (HCC) in Korea, following hepatitis B virus (HBV) infection and alcohol. HCV prevalence among Koreans older than 40 years of age has been estimated to be 1.29%. The prevalence of CHC increases with age, with the peak prevalence at the age of 60 or older. Blood transfusions have generated no risk of HCV infection since April 1991, when routine screening for anti-HCV in blood donors was adopted in Korea. Although injection drug use seems to be one of the most important risk factors of HCV infection among young adults in urban areas, the majority of CHC patients are not associated with injection drug use. Exposure to acupuncture was identified as a significant risk factor among older adults in rural areas. The mean age of patients with HCV-related cirrhosis and HCC was consistently about 10 years above that of patients associated with HBV. Genotypes 1b and 2a are the two most common types with almost equal proportions, and other genotypes are extremely rare. Korean patients with CHC have a high likelihood of responding to combination therapy with pegylated interferon and ribavirin, with a sustained virological response rate of 60-70% in patients with genotype 1 and 85-90% in those with genotype 2.
Antiviral Agents/therapeutic use
;
Genotype
;
Hepacivirus/genetics
;
Hepatitis C, Chronic/drug therapy/*epidemiology/transmission/virology
;
Humans
;
Korea/epidemiology
;
Prevalence
;
Risk Factors
10.The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C.
Yao XIE ; Dao-zhen XU ; Zhi-meng LU ; Kang-xian LUO ; Ji-dong JIA ; Yu-ming WANG ; Gui-zhen ZHAO ; Shu-lin ZHANG ; Da-zhi ZHANG
Chinese Journal of Hepatology 2004;12(2):72-75
OBJECTIVETo investigate the influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C.
METHODSThe genotypes of HCV virus were determined in the patients enrolled into the Randomized, opened and controlled trial of Peg-IFN alpha-2a (Pegasys) treatment, controlled with IFN-alpha-2a (Roferon-A), on chronic hepatitis C patients in China. The serum ALT levels and HCV RNA concentration of the patients were detected in the time of before treatment, the end of therapy and follow-up. The influence of HCV genotype on the IFN treatment of patients with chronic hepatitis C was analyzed in intention to treat (ITT) population.
RESULTSThe HCV genotypes of 202 cases were determined. 158 (78.2%) cases infected with genotype 1 HCV and 44 (21.8%) cases with genotype non-1. For overall patients, the viral response at the end of treatment (ETVR) and sustained viral response (SVR) rates were 53.8% and 25.3% respectively in patients with genotype 1 HCV, but in genotype non-1 patients those was 61.4% and 43.2%, and the difference of SVR between genotype 1 and non-1 was significant (P=0.021). After grouped by the used drugs, in the patients given Pegasys treatment, the ETVR rates of patients with genotype 1 and non-1 HCV infection were 76.8% and 81.0%, the difference was not significant (P=0.686), but the difference of SVR rates, which were 35.4% and 66.7%, of the patients was significant (P=0.01). The viral relapse rate of genotype 1 was 55.6%; it was significant higher than that of genotype non-1 (23.5%) (P=0.02). In Roferon-A group, the ETVR and SVR rates of patients with genotype 1 HCV were 29.0% and 14.5%, which were lower, but not significant, than those of patients with genotype non-1 (43.5% and 21.7%). The viral relapse rate of genotype 1 was 72.7% and higher, but not significant, than that of genotype non-1 also (50.0%) (P=0.21).
CONCLUSIONHCV genotype could affects the efficacies, mainly the sustained responses, of IFN treatment of patients with chronic hepatitis C, and the effects of IFN were related to the kinds of drugs and therapeutic course.
Antiviral Agents ; therapeutic use ; Genotype ; Hepacivirus ; classification ; genetics ; Hepatitis C, Chronic ; drug therapy ; virology ; Humans ; Interferon-alpha ; therapeutic use ; Polyethylene Glycols ; therapeutic use ; Recombinant Proteins ; Recurrence